Cat. No：GM-87810MAB
Product：Anti-c-Kit(CD117) hIgG1 Reference Antibody (Bribio)
Cat. No：GM-87810MAB
Product：Anti-c-Kit(CD117) hIgG1 Reference Antibody (Bribio)
GM-87810MAB-1mg / 1 mg
GM-87810MAB-5mg / 5 mg
GM-87810MAB-25mg / 25 mg
GM-87810MAB-50mg / 50mg
GM-87810MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target c-Kit
Clone Briquilimab
Alternative Names C-Kit, CD117, MASTC, PBT, SCFR
Source/Isotype Monoclonal Human IgG1, Kappa
Application /
Description CD117 (also known as c-KIT or SCF receptor) is a gene that encodes the Stem Cell Factor Receptor (SCFR) and belongs to the type I tyrosine kinase receptor family. Briquilimab works by binding to CD117, blocking the function of the Stem Cell Factor receptor and thereby affecting the behavior of cells dependent on the CD117 signaling pathway. As an innovative monoclonal antibody targeting CD117, Briquilimab has shown significant potential in hematopoietic stem cell transplantation, immune regulation, and the treatment of related diseases, making it a promising low-toxicity and highly effective novel therapy.
Formulation Phosphate-buffered solution, pH 7.4.
Cat. No：GM-87810MAB
Product：Anti-c-Kit(CD117) hIgG1 Reference Antibody (Bribio)
GM-87810MAB-1mg / 1 mg
GM-87810MAB-5mg / 5 mg
GM-87810MAB-25mg / 25 mg
GM-87810MAB-50mg / 50mg
GM-87810MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target c-Kit
Clone Briquilimab
Alternative Names C-Kit, CD117, MASTC, PBT, SCFR
Source/Isotype Monoclonal Human IgG1, Kappa
Application /
Description CD117 (also known as c-KIT or SCF receptor) is a gene that encodes the Stem Cell Factor Receptor (SCFR) and belongs to the type I tyrosine kinase receptor family. Briquilimab works by binding to CD117, blocking the function of the Stem Cell Factor receptor and thereby affecting the behavior of cells dependent on the CD117 signaling pathway. As an innovative monoclonal antibody targeting CD117, Briquilimab has shown significant potential in hematopoietic stem cell transplantation, immune regulation, and the treatment of related diseases, making it a promising low-toxicity and highly effective novel therapy.
Formulation Phosphate-buffered solution, pH 7.4.
